Glancy Prongay & Murray LLP Announces the Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Adamas Pharmaceuticals, Inc. - ADMS

Stock Information for Diagnos Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Diagnos Inc.

ADMA Biologics Set to Join S&P SmallCap 600 Index
ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference
Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
ADMA Biologics Announces Partial Paydown of Revolving Credit Facility
ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update
ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.